for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zhejiang Huahai Pharmaceutical Co., Ltd.

600521.SS

Latest Trade

15.02CNY

Change

-0.17(-1.12%)

Volume

14,158,206

Today's Range

14.77

 - 

15.32

52 Week Range

9.80

 - 

22.20

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
15.19
Open
15.26
Volume
14,158,206
3M AVG Volume
326.53
Today's High
15.32
Today's Low
14.77
52 Week High
22.20
52 Week Low
9.80
Shares Out (MIL)
1,250.84
Market Cap (MIL)
19,000.24
Forward P/E
23.63
Dividend (Yield %)
--

Latest Developments

More

Zhejiang Huahai Pharmaceutical's Senior Executive Cai Minda Passes Away Due To Illness

U.S. FDA Releases Warning Letter To Zhejiang Huahai Pharmaceutical

Zhejiang Huahai Pharmaceutical Clarifies Reports Related To Sandoz's Product Recall

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zhejiang Huahai Pharmaceutical Co., Ltd.

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.

Industry

Biotechnology & Drugs

Contact Info

Xunqiao, Linhai City

+86.576.85991096

http://en.huahaipharm.com

Executive Leadership

Jun Du

Vice Chairman of the Board

Mei Zhang

Chief Financial Officer, Finance Director

Baohua Chen

General Manager, Director

Yong Hua Zhu

Deputy General Manager, Secretary of the Board, Director

Qimao Chen

Deputy General Manager

Key Stats

4.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

4.1K

2017

5.0K

2018

5.1K

2019(E)

5.9K
EPS (CNY)

2016

0.408

2017

0.517

2018

0.086

2019(E)

0.643
Price To Earnings (TTM)
89.24
Price To Sales (TTM)
3.65
Price To Book (MRQ)
4.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
102.95
LT Debt To Equity (MRQ)
11.21
Return on Investment (TTM)
4.36
Return on Equity (TTM)
2.41

Latest News

BRIEF-Zhejiang Huahai Pharmaceutical Clarifies Reports Related To Sandoz's Product Recall

* SAYS IT CLARIFIES ONLINE REPORTS ON HUAHAI BEING INVOLVED IN MANUFACTURING RAW MATERIALS CONTAINING NDEA IMPURITIES THAT PROMPTED SANDOZ TO RECALL A BATCH OF ITS LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE TABLETS

EU places China's Zhejiang Huahai under increased supervision

European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, in the latest crackdown on the Chinese firm after a probable carcinogen was found in its blood pressure drug valsartan.

EU places China's Zheijiang Huahai under increased supervision

European authorities are placing Zhejiang Huahai Pharmaceutical Co Ltd under higher supervision, the European Medicines Agency said on Monday, after an inspection revealed lapses in quality management at the drugmaker's factory in China.

Embattled Chinese drug maker to get $43 mln in government support

A Chinese city government has given 300 million yuan ($43 million) to drug maker Zhejiang Huahai Pharmaceuticals, the company said, after it was recently faulted by U.S. and European regulators over production issues at one of its plants.

CORRECTED-(OFFICIAL)-UPDATE 3-FDA halts imports from China's Huahai Chuannan plant

The U.S. Food and Drug Administration said on Friday it will no longer allow imports of drug ingredients or medicines made with ingredients produced at China's Zhejiang Huahai Pharmaceuticals Chuannan factory, after a recall of one of its drugs that contained a probable...

Chinese drugmaker Huahai tumbles after FDA shutout

Shares of China's Zhejiang Huahai Pharmaceuticals Co Ltd <600521.SS> tumbled in early trade on Monday, the first day of trading since the U.S. Food and Drug Administration halted imports of drug ingredients or medicines made by the company.

Global health regulators find second toxin in common heart drug

(This version of the September 14th story changes final paragraph to show representative did not immediately respond to a request for comment)

Toxin at heart of drug recall shows holes in medical safety net

A toxin inadvertently produced in the manufacture of a widely prescribed medicine but not spotted for years raises questions about regulators' ability to detect risks in a sprawling global drug supply chain increasingly reliant on factories in China.

China tells medical institutions to stop using Huahai heart drug

China's health regulator has ordered local medical institutions to stop using a heart drug from Zhejiang Huahai Pharmaceutical Co Ltd, in a directive that comes just days after another case of a tainted medical product.

China orders medical institutions not to use recalled valsartan drug

China's health regulator has called on all medical institutions to cooperate with authorities and not use the valsartan blood and heart drug that is said to pose cancer risks.

BRIEF-Zhejiang Huahai Pharmaceutical's Preliminary 2017 Net Profit Up 26.45 Pct Y/Y

* SAYS PRELIM 2017 NET PROFIT UP 26.45 PERCENT Y/Y AT 633.29 MILLION YUAN ($101.16 million) Source text in Chinese: http://bit.ly/2Bf04WM Further company coverage: ($1 = 6.2600 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Huahai Pharmaceutical says fire accident in unit's warehouse

* Says fire accident has occurred at a warehouse of co's Zhejiang-based wholly owned pharmaceutical unit, on Jan. 18

BRIEF-Zhejiang Huahai Pharmaceutical to invest in pharma industry park project

* Says it plans to invest in pharma industry park project with total investment at about 10 billion yuan ($1.50 billion)

BRIEF-Zhejiang Huahai Pharmaceutical passes U.S. FDA approval

* Says it received approval for a kind of tablet, which is used for treatment of chronic hepatitis B, from U.S. Food and Drug Administration

BRIEF-Zhejiang Huahai Pharmaceutical passes FDA approval

* Says it received approval for its production base of API from U.S Food and Drug Administration

BRIEF-Zhejiang Huahai Pharmaceutical to use $30 mln to acquire shares of Eutilex

* Says co signs agreement to invest $30 million in Eutilex Co.,Ltd, which is mainly engaged in R&D of T cell therapy and antibody therapy products

BRIEF-Zhejiang Huahai Pharmaceutical passes U.S. FDA approval

* Says it received FDA approval for Paroxetine Capsules from U.S Food and Drug Administration

BRIEF-Zhejiang Huahai Pharma's prelim H1 net profit up 14.05 pct y/y

* Says preliminary H1 net profit up 14.05 percent y/y at 295.25 million yuan ($43.73 million)

BRIEF-Zhejiang Huahai Pharmaceutical to pay A shares annual div for FY 2016 on June 14

* Says it will pay cash dividend of 0.18 yuan(before tax)/share for 2016 to shareholders of record on June 13

BRIEF-Zhejiang Huahai Pharmaceutical to pay cash 1.8 yuan per 10 shares as FY 2016 div payment

* Says it plans to pay cash 1.8 yuan per 10 shares as FY 2016 div payment

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up